SUMMARY A case involving a gastric carcinoid in association with parathyroid adenoma is reported and the question of a possible link between these two ailments is discussed. This patient suffered from a parathyroid adenoma and a gastric carcinoid tumour. Given the rare occurrence of these two ailments (gastric carcinoids represent 2/1000 of gastric cancers and hyperparathyroidism affects some 1% of the general public), it seems unlikely that they occur simultaneously by chance. Moreover, carcinoid tumours of the stomach account for less than 3% of carcinoid tumours of the digestive tract. ' One could suggest a carcinoid triggered hyperparathyroidism. The gastric tumour, however, was secreting serotonin and it is difficult to see how this could trigger a compensatory hyperparathyroidism. group.bmj.com on June 20, 2017 -Published by http://gut.bmj.com/ Downloaded from
(2*88 mmol/l=116 mg/l) and hypophosphataemia (0.69 mmol/l=21 mg/l). The pain persisted and at surgery a nut sized (6x10 mm) oxalic stone was removed. The This patient suffered from a parathyroid adenoma and a gastric carcinoid tumour. Given the rare occurrence of these two ailments (gastric carcinoids represent 2/1000 of gastric cancers and hyperparathyroidism affects some 1% of the general public), it seems unlikely that they occur simultaneously by chance. Moreover, carcinoid tumours of the stomach account for less than 3% of carcinoid tumours of the digestive tract. ' One could suggest a carcinoid triggered hyperparathyroidism. The gastric tumour, however, was secreting serotonin and it is difficult to see how this could trigger a compensatory hyperparathyroidism. over, after removal of the gastric tumour serotonin values in the urine became normal and hyperparathyroidism set in. Finally, after parathyroid adenomectomy, calcium concentrations remained normal and there was no appearance of hyperparathyroidism, in spite of the development of several carcinoid hepatic metastasis. The action of serotonin secretion thus does not appear to trigger the development of hyperparathyroidism, and we shall have to place our observations along with type I (MEN I) multiple endocrine neoplasias.
A case identical to this one was not found on reviewing the literature. One report2 lists three patients in which primary hyperparathyroidism is associated with a carcinoid tumour of the digestive tract. Unlike our case, however, the carcinoid was ileal in two instances and duodenal in the other. Moreover, the carcinoids secreted calcitonin and not serotonin. Metastasis were present in two patients. There was no family history. The authors concluded that this association fell under Type I MEN. But, contrary to serotonin secretion, could exaggerated calcitonin secretion not promote a hyperparathyroid reaction?3 In this case, when thyroid medullary cancers involve calcitonin secretion, hyperparathyroidism would tend more to be a compensating mechanism4 than part of the Sipple syndrome (MEN 2).5 Another publication reports a case of gastric carcinoids associated with hyperparathyroidism.' Tumour secretion included gastrin. The authors concluded that this association came under type I MEN.
Hyperparathyroidism/carcinoid association should be seen as a rare form of MEN I and patients with digestive tract carcinoids should systematically be examined for hyperparathyroidism. 
